Front Row with BioCentury: Cancer’s next wave

Cancer research is entering a period of rapid translational progress, as advances in targeted therapies, antibody-drug conjugates (ADCs), and cell therapies begin to unlock new opportunities in some of oncology’s most challenging diseases. In this episode of Front Row with BioCentury, Executive Director of Pharma Intelligence Lauren Martz examines the scientific breakthroughs emerging from AACR and ASCO, and explains how these innovations are translating into new clinical strategies across the cancer landscape.

In this conversation, Martz highlights the growing momentum in pancreatic cancer, where promising data from pan-RAS inhibitors have fueled optimism that the field may be approaching a long-awaited inflection point. She discusses how researchers are building on these advances through next-generation RAS-targeting approaches, novel combinations, and a growing pipeline of ADCs, while also exploring the more than 170 emerging oncology targets aimed at enhancing antitumor immunity, overcoming resistance, and expanding the reach of precision medicine...